pulmonari
complic
common
allogen
hematopoiet
stem
cell
transplant
hsct
adult
hsct
recipi
reportedli
experi
pulmonari
complic
repres
major
caus
mortal
children
undergo
hsct
incid
pulmonari
complic
vari
onset
poor
prognost
event
carri
significantli
increas
risk
mortal
one
time
pulmonari
complic
directli
relat
infect
today
howev
noninfecti
pulmonari
complic
idiopath
pneumonia
syndrom
ip
bronchiol
obliteran
syndrom
bo
seen
frequent
respiratori
viru
rv
infect
occur
hsct
recipi
previou
studi
examin
progress
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
describ
risk
factor
progress
report
associ
earli
rv
infect
late
obstruct
lung
injuri
associ
rv
infect
alloimmun
lung
transplant
recipi
recent
report
lung
transplant
recipi
develop
acut
chronic
graft
reject
common
rv
infect
earli
day
transplant
isol
alloimmun
lung
diseas
ie
bo
ip
hsct
suggest
specif
trigger
make
lung
target
organ
alloreact
line
process
reflect
current
view
develop
alloreact
tissu
damag
result
releas
inflammatori
cytokin
result
activ
influx
lymphocyt
specul
presenc
common
rv
might
trigger
alloimmun
lung
syndrom
allol
hsct
prospect
studi
influenc
rv
develop
allol
overal
surviv
os
cohort
pediatr
hsct
recipi
patient
underw
allogen
hsct
januari
may
pediatr
hematolog
immunolog
depart
wilhelmina
children
hospitalunivers
medic
center
includ
prospect
studi
patient
enrol
hsct
protocol
provid
written
inform
consent
hsct
research
protocol
patient
receiv
antiemet
drug
prophylact
anticonvuls
therapi
clonazepam
given
patient
receiv
busulfan
antibiot
prophylaxi
involv
daili
ciprofloxacillin
fluconazol
start
condit
resolut
neutropenia
day
neutrophilsml
addit
prophylaxi
streptococcu
viridan
mucos
phase
given
cefazolin
start
month
transplant
cotrimoxazol
time
week
given
pneumocysti
carinii
pneumonia
prophylaxi
case
posit
serolog
herp
simplex
viru
prophylaxi
acyclovir
administ
prophylaxi
virus
given
igg
level
check
everi
week
intraven
immunoglobulin
given
patient
igg
level
gl
graftversushost
diseas
gvhd
prophylaxi
consist
cyclosporin
aim
trough
level
mgl
base
nation
protocol
guidelin
supplement
methylprednisolon
mp
mg
kgday
day
patient
receiv
cord
blood
cb
transplant
methotrex
short
cours
mg
day
patient
receiv
unrel
bone
marrow
bm
peripher
blood
stem
cell
pbsc
transplant
patient
receiv
unrel
donor
graft
cb
bm
pbsc
antithymocyt
globulin
atg
serotherapi
administ
day
atgfreseniu
patient
acut
lymphoblast
leukemia
thymoglobulin
indic
monitor
bacteri
colon
nosethroat
swab
stool
cultur
weekli
process
accord
standard
microbiolog
procedur
june
test
galactomannan
platelia
aspergillu
enzym
immunoassay
biorad
hercul
ca
case
suspect
aspergillu
infect
base
clinic
symptom
prolong
fever
system
broad
antibiot
therapi
radiolog
find
june
routin
monitor
galactomannan
twice
weekli
plasma
test
weekli
epsteinbarr
viru
ebv
cytomegaloviru
cmv
human
herp
viru
adenoviru
dna
posit
realtim
polymeras
chain
reaction
pcr
see
next
section
patient
deem
posit
viral
load
cpml
test
done
twice
week
adenoviru
viral
load
cpml
treat
preemptiv
cidofovir
cmv
viral
load
cpml
treat
preemptiv
foscavir
ganciclovir
depend
viral
load
immunosuppress
regimen
sign
posttransplant
lymphoprolif
diseas
ebv
treat
preemptiv
rituximab
august
nasal
pharyng
aspir
npa
sampl
obtain
pcr
presenc
symptom
urti
lrti
day
posttransplant
august
onward
perform
surveil
studi
npa
sampl
patient
admit
hsct
unit
reversetranscriptas
rt
pcr
done
common
rv
see
later
repeat
npa
weekli
patient
neg
rv
twice
weekli
patient
posit
rv
nucleic
acid
extract
use
total
nucleic
acid
protocol
magna
pure
lc
nucleic
acid
isol
system
roch
diagnost
basel
switzerland
detect
rna
virus
cdna
synthes
use
multiscrib
rt
random
hexam
appli
biosystem
foster
citi
ca
detect
viral
atyp
pathogen
perform
parallel
use
realtim
pcr
assay
specif
follow
virus
cmv
ebv
respiratori
syncyti
viru
b
influenzaviru
b
parainfluenzaviru
rhinovirus
adenovirus
human
coronavirus
human
metapneumoviru
mycoplasma
pneumonia
chlamydia
pneumonia
realtim
pcr
procedur
perform
describ
previous
brief
sampl
assay
duplic
reaction
mixtur
contain
ml
cdna
ml
taqman
univers
pcr
master
mix
appli
biosystem
nmoll
forward
revers
primer
nmoll
probe
sampl
spike
extract
intern
control
viru
murin
encephalomyocard
viru
rna
viru
porcin
herpesviru
dna
viru
monitor
effici
extract
amplif
essenti
describ
previous
cycl
threshold
ct
give
impress
quantiti
viral
load
ie
semiquantit
valu
patient
observ
sign
respiratori
diseas
earli
late
transplant
clinic
symptom
record
patient
urti
symptom
npa
sampl
obtain
test
rv
infect
pcr
see
earlier
patient
sign
lrti
chest
xray
obtain
test
perform
indic
includ
bronchoalveolar
lavag
bal
broad
infecti
screen
bacterialfung
cultur
viral
pcr
galactomannan
well
highresolut
comput
tomographi
hrct
scan
case
suspect
allol
hrct
bal
alway
perform
see
definit
diseas
shortli
perform
pulmonari
function
test
pft
difficult
young
children
cohort
routin
pft
transplant
perform
children
age
year
pft
also
perform
children
respiratori
symptom
short
breath
dri
cough
tachypnea
discharg
patient
diagnosi
allol
pft
repeat
least
monthli
disord
resolv
patient
age
year
underw
spirometri
test
technic
possibl
bodi
plethysmographi
co
diffus
test
accord
european
respiratori
societi
guidelin
total
lung
capac
tlc
forc
expiratori
volum
second
fev
express
percentag
predict
normal
valu
use
publish
equat
children
adult
give
tlc
predict
fev
predict
tlc
predict
design
restrict
pattern
fev
predict
fev
forc
vital
capac
fvc
obstruct
pattern
tlc
predict
fev
fvc
mix
pattern
co
diffus
impair
diffus
urti
defin
rhinorrhea
andor
dri
cough
lrtipneumonia
defin
cough
andor
fever
pulmonari
infiltr
chest
xray
elev
creactiv
protein
andor
posit
microbiolog
cultur
sputum
bal
fluid
blood
ip
defin
presenc
acut
bilater
pulmonari
infiltr
cough
dyspnea
hypoxemia
absenc
infect
exclud
rv
heart
failur
definit
ip
includ
entiti
diffus
alveolar
bleed
periengraft
syndrom
bo
defin
typic
hrct
chang
bronchial
wall
thicken
air
trap
mosaic
parenchym
attenu
absenc
sign
infect
whenev
pulmonari
function
test
could
done
abnorm
pulmonari
function
test
result
ie
decreas
fev
fev
fvc
bronchiol
obliteran
organ
pneumonia
boop
defin
restrict
pft
pft
done
consolid
chest
xray
allol
defin
ip
bo
boop
subdivid
acut
ip
chronic
bosboop
form
gener
urti
treat
patient
influenza
neuraminidas
inhibitor
administ
lrtipneumonia
treat
empir
antibiot
therapi
vancomycin
ceftazidim
whenev
bacteri
pathogen
found
therapi
adjust
accord
antibiot
resist
patient
probabl
proven
aspergillu
spp
voriconazol
administ
respons
voriconazol
note
progress
clinic
radiolog
find
granulocyt
transfus
given
allol
treat
mp
mgkgday
iv
day
mgkgday
thereaft
taper
per
week
mgkgday
mp
puls
repeat
everi
week
recoveri
maximum
cours
recoveri
defin
normal
pft
andor
resolv
symptom
extra
oxygen
requir
subsequ
cours
mp
prednison
mgkgday
given
immunosuppress
agent
usual
cyclosporin
continu
addit
azythromycin
given
suggest
immunomodulatori
effect
along
immunosuppress
therapi
support
care
provid
extra
oxygen
mechan
ventil
necessari
igg
level
maintain
gl
primari
endpoint
studi
develop
acut
chronic
allol
secondari
endpoint
os
differ
rvposit
rvneg
group
test
use
pearson
c
test
result
p
valu
consid
statist
signific
durat
followup
time
endpoint
develop
allol
death
last
assess
survivor
analyz
risk
factor
outcom
consid
variabl
associ
recipi
age
transplant
sex
cmv
serolog
rv
posit
singlemultipl
virus
diseas
malign
vs
nonmalign
donortransplant
techniqu
cell
sourc
hla
dispar
donor
relationship
condit
regimen
hsct
complic
allol
acut
gvhd
agvhd
cmv
adenoviru
plasma
dna
posit
venoocclus
diseas
relaps
examin
influenc
variou
virus
primari
endpoint
rhinoviru
compar
virus
multipl
viral
infect
compar
singl
viral
infect
analys
test
allol
group
ip
bosboop
base
hypothesi
earli
viral
infect
might
trigger
acut
chronic
allol
addit
test
syndrom
separ
ie
bosboop
exclud
ip
analys
ip
exclud
bosboop
associ
variabl
includ
recipi
diseas
hsct
techniqu
primari
endpoint
evalu
use
cox
proport
hazard
model
dichotom
outcom
eg
allol
yesno
use
depend
variabl
predictor
use
independ
variabl
univari
predictor
outcom
p
valu
use
multivari
analysi
result
express
hazard
ratio
hr
correspond
confid
interv
ci
ci
includ
consid
statist
signific
analys
associ
hsct
complic
primari
endpoint
allol
well
secondari
endpoint
os
done
use
logist
regress
dichotom
outcom
eg
allol
surviv
yesno
use
depend
variabl
predictor
use
independ
variabl
univari
predictor
outcom
p
valu
use
multivari
logist
regress
analysi
result
express
odd
ratio
or
correspond
ci
ci
includ
consid
statist
signific
probabl
allol
os
calcul
use
kaplanmei
estim
logrank
test
use
comparison
statist
analys
perform
use
spss
spss
inc
chicago
il
total
patient
includ
studi
januari
august
routin
npa
test
august
may
six
patient
underw
transplant
period
exclud
studi
experienc
autolog
recoveri
n
earli
graft
reject
within
month
transplant
n
earli
death
engraft
n
thu
consid
prone
alloreact
diseas
median
age
transplant
year
rang
month
year
bodi
weight
rang
kg
baselin
characterist
rvposit
rvneg
group
shown
tabl
signific
differ
group
evid
although
slightli
match
donor
transplant
rvneg
group
cb
donor
rvposit
group
cohort
patient
rv
infect
median
day
onset
day
posttransplant
rang
day
day
symptom
usual
mild
major
patient
rv
infect
n
urti
symptom
eleven
patient
requir
extra
oxygen
patient
need
ventil
support
associ
bacteri
infect
two
patient
influenza
infect
treat
neuraminidas
inhibitor
patient
experienc
spontan
clinic
recoveri
within
day
although
symptom
disappear
viru
detect
npa
sampl
week
month
afterward
high
viral
load
pcr
ct
valu
see
patient
method
thirtyeight
patient
singl
rv
patient
multipl
virus
patient
rv
detect
clinic
pictur
typic
rv
infect
patient
mild
respiratori
symptom
rhinorrhea
caus
recov
spontan
distribut
variou
virus
shown
tabl
thirti
patient
diagnos
allol
bo
ip
patient
develop
boop
one
patient
present
pulmonari
hypertens
histolog
proven
vasculopathi
lymphocyt
infiltr
respond
immunosuppress
agent
consid
patient
ip
patient
allol
median
time
onset
week
rang
week
transplant
ip
occur
earlier
median
time
onset
week
rang
week
bo
develop
later
median
week
rang
week
univari
analysi
rv
posit
cb
stem
cell
graft
chemotherapybas
condit
regimen
predictor
develop
allol
tabl
median
durat
rv
posit
develop
allol
week
rang
week
figur
time
develop
rv
posit
seem
import
well
patient
rvposit
earli
transplant
median
day
slightli
greater
likelihood
develop
allol
becam
rvposit
day
hr
ci
p
univari
analysi
influenc
hsctassoci
complic
allol
show
adenoviru
reactiv
ci
p
predict
allol
agvhd
grade
iiiv
organ
appear
neg
predictor
ci
p
multivari
analysi
agvhd
remain
strong
predictor
prevent
allol
ci
p
influenc
agvhd
develop
allol
whole
group
rvposit
patient
shown
figur
c
studi
agvhd
clearli
develop
onset
allol
mean
time
onset
week
gvhd
rang
week
week
allol
rang
week
particular
rvposit
group
agvhd
grade
iiiv
anoth
organ
strongli
protect
develop
allol
found
influenc
differ
individu
viral
speci
presenc
singl
viru
multipl
virus
develop
allol
data
shown
patient
develop
allol
treat
accord
protocol
mp
puls
therapi
discuss
earlier
patient
demonstr
prompt
initi
improv
clinic
symptom
os
median
follow
week
rang
week
caus
death
relaps
patient
nonrelaps
mortal
patient
fourteen
patient
allol
die
transplantationrel
caus
refractori
agvhd
invas
fungal
infect
adenoviru
diseas
sudden
cardiac
death
unknown
caus
ongo
lung
diseas
univari
analysi
identifi
adenoviru
reactiv
ci
p
develop
allol
ci
p
predictor
lower
surviv
relaps
signific
influenc
os
hr
ci
p
multivari
analysi
allol
remain
predictor
cohort
ci
p
impact
allol
os
depict
figur
cohort
patient
high
incid
earli
rv
infect
occur
median
day
hsct
rhinoviru
infect
common
rv
detect
rv
infect
usual
mild
clinic
cours
patient
experienc
spontan
recoveri
within
week
rv
infect
occur
first
day
hsct
appear
sole
predictor
develop
acut
chronic
allol
found
patient
patient
recov
initi
urti
symptom
new
episod
respiratori
symptom
occur
lead
diagnosi
allol
presenc
singl
rv
multipl
rv
presenc
rhinoviru
nonrhinoviru
rv
associ
develop
allol
paradox
agvhd
protect
effect
develop
allol
like
result
prolong
immunosuppress
therapi
patient
agvhd
patient
allol
initi
exhibit
good
clinic
respons
mp
puls
therapi
develop
allol
associ
high
mortal
howev
possibl
weak
studi
chang
polici
test
rv
studi
period
earli
phase
studi
test
npa
sampl
rv
patient
exhibit
symptom
later
studi
period
signific
rv
recogn
weekli
surveil
assay
done
patient
surveil
assay
identifi
rvposit
patient
without
symptom
time
sampl
howev
patient
develop
urti
symptom
within
day
posit
sampl
rv
would
ultim
detect
regardless
test
polici
thu
believ
miss
rvposit
patient
presurveil
period
chang
test
polici
major
impact
result
data
shown
differ
median
time
rv
posit
would
shorter
monitor
whole
group
routin
three
patient
symptom
clinic
cours
typic
viral
urti
consid
rvposit
despit
neg
rvpcr
result
patient
symptom
might
result
viru
detect
pcr
panel
would
interest
test
recent
identifi
virus
boca
wuki
obviou
symptom
fact
studi
group
includ
similar
patient
analys
decid
well
consid
patient
rvneg
analysi
result
would
patient
develop
allol
realiz
may
well
miss
mild
urti
symptom
period
discharg
day
full
data
rv
posit
discharg
hospit
patient
rvpcrneg
discharg
develop
allol
howev
acquisit
rv
earli
hsct
appear
import
develop
allol
patient
rvposit
within
day
hsct
tend
suscept
allol
remark
definit
ip
warrant
consensu
definit
ip
establish
nation
institut
health
workshop
infecti
agent
includ
rv
exclud
patient
observ
prolong
shed
rv
month
thu
could
formal
diagnos
ip
patient
initi
urti
symptom
disappear
spontan
within
week
howev
subsequ
period
least
day
without
signific
respiratori
problem
symptom
hypoxia
andor
airway
obstruct
recur
believ
repres
direct
progress
viral
infect
rather
combin
sever
factor
alloreact
trigger
tissu
damag
persist
viral
infect
play
pivot
role
therefor
chose
defin
ip
discuss
earlier
take
account
presenc
rv
identifi
pcr
done
studi
moreov
formal
definit
ip
promulg
era
molecular
diagnosi
rv
yet
avail
hypothes
rv
may
contribut
pathogenesi
allol
follow
rv
damag
respiratori
epithelium
caus
inflammatori
respons
time
immun
recoveri
normal
ip
bosboop
view
distinct
clinic
entiti
first
studi
separ
note
strong
associ
among
rv
posit
gvhd
os
group
combin
ip
bosboop
subsequ
analys
also
combin
bm
pbsc
sourc
analysi
would
interest
evalu
patient
receiv
pbsc
separ
group
appar
higher
risk
chronic
gvhd
cgvhd
small
number
patient
cohort
receiv
pbsc
n
preclud
meaning
analysi
howev
numer
studi
explor
incid
outcom
nosocomi
communityacquir
rv
infect
hsct
report
incid
vari
wide
rang
incid
explain
differ
among
studi
definit
rv
infect
period
monitor
rv
infect
eg
inpatientsoutpati
season
influenc
sensit
analysi
method
use
cohort
high
incid
rv
urti
might
attribut
close
monitor
respiratori
symptom
perform
rtpcr
surveil
assay
addit
nosocomi
rv
infect
frequent
observ
genotyp
studi
suggest
spread
throughout
ward
studi
period
also
contribut
rel
high
incid
data
shown
literatur
data
morbid
associ
rv
infect
hsct
conflict
group
found
progress
viral
urti
lrti
patient
hsct
wherea
other
report
progress
patient
cohort
found
direct
progress
lrti
almost
patient
mild
urti
symptom
recov
spontan
median
day
onset
rv
infect
day
cohort
compar
least
day
previou
studi
progress
lrti
might
expect
patient
rv
infect
earli
transplant
poor
immun
statu
seen
opinion
like
moment
immun
recoveri
defin
onset
symptom
defin
ip
studi
ie
symptom
period
quiescent
rv
infect
might
report
studi
progress
viral
pneumonia
symptom
occur
onset
rv
infect
later
hsct
immun
recoveri
alreadi
occur
report
incid
ip
hsct
rang
patient
bo
rang
report
data
adult
studi
combin
incid
allol
cohort
compar
report
literatur
incid
ip
rel
high
like
cohort
includ
high
number
earli
rvposit
patient
found
strong
associ
rv
infect
develop
allol
best
knowledg
first
report
strong
associ
rv
infect
lifethreaten
allol
earlier
erard
et
al
describ
relationship
rv
infect
first
day
hsct
declin
airflow
lead
increas
overal
mortal
declin
airflow
detect
immedi
infect
return
baselin
valu
suggest
sustain
airway
inflamm
lead
perman
loss
lung
function
pulmonari
diseas
much
sever
cohort
compar
cohort
erard
et
al
discrep
explain
earli
moment
rv
infect
immun
recoveri
yet
occur
persist
rv
like
caus
tissu
damag
ultim
result
stronger
inflammatori
respons
absenc
immun
time
primari
rv
infect
also
might
explain
absenc
immedi
declin
clinic
lung
function
pulmonari
function
deterior
least
week
rv
infect
first
sign
immun
recoveri
evid
would
interest
routin
perform
pft
earlier
hsct
reason
hygien
patient
comfort
decid
present
studi
previou
studi
found
associ
presenc
gvhd
develop
allol
studi
agvhd
associ
ip
risk
factor
includ
condit
regimen
infect
might
involv
well
cgvhd
consid
import
risk
factor
bo
adult
alloreact
cell
context
agvhd
cgvhd
play
import
role
bo
bo
also
seen
absenc
cgvhd
patient
howev
percentag
may
differ
children
less
suscept
cgvhd
find
agvhd
grade
iiiv
organ
protect
effect
develop
allol
necessarili
contradict
result
like
agvhd
allol
manifest
alloimmun
specul
appar
protect
effect
agvhd
reflect
influenc
alloreact
cell
immunosuppress
agent
use
treat
agvhd
grade
iiiv
none
patient
lung
involv
onset
agvhd
may
lung
less
suscept
acut
alloreact
classic
target
organ
gut
liver
skin
also
reflect
fact
median
time
allol
longer
week
median
time
agvhd
week
patient
develop
allol
taper
immunosuppress
therapi
therapi
stop
patient
agvhd
prolong
immunosuppress
therapi
includ
steroid
thu
like
less
chanc
develop
alloimmun
lung
word
rvposit
patient
develop
allol
significantli
greater
immun
suppress
rvposit
patient
develop
allol
data
shown
effect
immunosuppress
therapi
develop
allol
line
previou
find
regard
cgvhd
contrast
studi
cohort
patient
bo
sign
cgvhd
organ
find
associ
cgvhd
bosboop
might
gener
low
incid
cgvhd
pediatr
hsct
popul
togeth
fact
viral
infect
frequent
childhood
might
make
respiratori
epithelium
preferenti
target
chronic
alloreact
least
pediatr
cohort
protect
effect
cgvhd
develop
allol
note
like
cgvhd
mainli
limit
form
treat
system
immunosuppress
agent
eg
steroid
similar
associ
rv
infect
allol
report
lung
transplant
recent
prospect
cohort
studi
lung
transplant
recipi
clearli
show
significantli
acut
chronic
reject
episod
patient
rv
infect
occur
within
day
posttransplant
bo
occur
lung
transplant
consid
manifest
allograft
reject
alloimmun
process
anim
model
lung
transplant
demonstr
associ
presenc
rv
develop
bo
exclus
allogen
transplant
set
result
line
associ
rv
infect
allol
seen
hsct
popul
strongli
support
hypothesi
airway
damag
rv
infect
alon
lead
sever
problem
trigger
alloimmun
strong
associ
current
practic
lung
transplant
increas
immunosuppress
ad
steroid
presenc
rv
infect
posttransplant
avoid
reject
person
commun
lung
transplant
programm
umc
groningen
umc
utrecht
practic
led
decreas
graft
reject
rate
increas
immunosuppress
sole
presenc
rv
may
sound
paradox
possibl
predispos
patient
potenti
lifethreaten
complic
support
observ
patient
rv
infect
earli
hsct
less
vulner
allol
receiv
immunosuppress
agvhd
present
predict
rvposit
patient
actual
risk
develop
allol
earli
recognit
diseas
detect
biomark
associ
lung
damag
develop
allol
identif
certain
risk
group
studi
genet
polymorph
innat
immun
patient
might
addit
valu
finetun
initi
adjust
immunosuppress
therapi
hsct
set
conclus
shown
clear
relat
earli
rv
infect
develop
allol
pediatr
hsct
recipi
tissu
damag
persist
rv
lung
might
trigger
develop
allol
agvhd
like
greater
immunosuppress
agvhd
appear
protect
allol
find
suggest
prevent
rv
infect
earli
hsct
utmost
import
addit
prolong
immun
suppress
transplant
recipi
rv
infect
might
prevent
develop
allol
analog
current
practic
lung
transplant
birgitta
versluy
design
studi
provid
clinic
data
analyz
data
wrote
paper
john
rossen
develop
perform
viral
pcr
assay
rob
schuurman
develop
perform
viral
pcr
assay
bart
van
ewijk
perform
pulmonari
function
test
marc
bier
design
studi
provid
clinic
data
jaap
jan
boelen
design
studi
provid
clinic
data
perform
statist
analysi
wrote
paper
financi
disclosur
author
conflict
interest
disclos
